Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
South Korean military plans to launch new division for future warfare
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
SK Bioscience CEO says financing ready for M&As
By Kan Hyeong-wooPublished : March 31, 2022 - 15:31
SK Bioscience will look to spend “trillions of won” on aggressive mergers and acquisitions in taking the next step to become a vaccine and bio powerhouse, CEO Ahn Jae-yong said Thursday.
“We will secure more funding through the assets compiled with the (initial public offering), operating cash and additional acquisition financing,” he said in an online press conference to mark the company’s one-year anniversary of going public.
“We will use the funding on expanding the company through M&As and the COVID-19 vaccine portfolio while strengthening the overall vaccine business and increasing the infrastructure to achieve a new quantum jump.”
Referring to active investments as “inorganic growth,” the CEO said the company is currently in talks with multiple companies for strategic investments and setting up cooperative models of research and development. SK Bioscience will strengthen its vaccine competitiveness even further through M&As with global vaccine developers and in-licensing, he added.
On top of the existing business of its COVID-19 vaccine’s contract manufacturing organization, Ahn pointed out that the company will enter the market of cell and gene therapy beginning with the contract development and manufacturing organization of viral vectors.
Regarding SK Bioscience’s coronavirus vaccine candidate GBP510, the CEO expects it to be authorized by the Ministry of Food and Drug Safety within the first half of this year as estimated earlier. He noted that the result of the third and last phase of the clinical trials will be announced before the end of April. SK Bioscience previously inked a pre-contract deal with the Korean government for 10 million doses of the vaccine worth of 200 billion won ($165 million).
Besides developing GBP510, Ahn revealed that the company will soon showcase a nasal spray that uses protein-targeting technology.
“If you use the nasal spray in your nose, it will help you block the coronavirus infection for the next one to 10 days,” he said.
The CEO also highlighted that the company is in talks with various countries and international firms in a bid to expand its global footprint. He said SK Bioscience will later announce plans on setting up production footholds in the Middle East and Southeast Asia.
“We will secure more funding through the assets compiled with the (initial public offering), operating cash and additional acquisition financing,” he said in an online press conference to mark the company’s one-year anniversary of going public.
“We will use the funding on expanding the company through M&As and the COVID-19 vaccine portfolio while strengthening the overall vaccine business and increasing the infrastructure to achieve a new quantum jump.”
Referring to active investments as “inorganic growth,” the CEO said the company is currently in talks with multiple companies for strategic investments and setting up cooperative models of research and development. SK Bioscience will strengthen its vaccine competitiveness even further through M&As with global vaccine developers and in-licensing, he added.
On top of the existing business of its COVID-19 vaccine’s contract manufacturing organization, Ahn pointed out that the company will enter the market of cell and gene therapy beginning with the contract development and manufacturing organization of viral vectors.
Regarding SK Bioscience’s coronavirus vaccine candidate GBP510, the CEO expects it to be authorized by the Ministry of Food and Drug Safety within the first half of this year as estimated earlier. He noted that the result of the third and last phase of the clinical trials will be announced before the end of April. SK Bioscience previously inked a pre-contract deal with the Korean government for 10 million doses of the vaccine worth of 200 billion won ($165 million).
Besides developing GBP510, Ahn revealed that the company will soon showcase a nasal spray that uses protein-targeting technology.
“If you use the nasal spray in your nose, it will help you block the coronavirus infection for the next one to 10 days,” he said.
The CEO also highlighted that the company is in talks with various countries and international firms in a bid to expand its global footprint. He said SK Bioscience will later announce plans on setting up production footholds in the Middle East and Southeast Asia.
